Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
meropenem sun stungulyfs-/innrennslisstofn, lausn 1 g
sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 1 g
Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
meropenem sun stungulyfs-/innrennslisstofn, lausn 500 mg
sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 500 mg
Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
methylphenidate stada hart hylki með breyttan losunarhraða 30 mg
stada arzneimittel ag - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg
Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
methylphenidate stada hart hylki með breyttan losunarhraða 20 mg
stada arzneimittel ag - methylphenidatum hýdróklóríð; methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 20 mg
Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
methylphenidate stada hart hylki með breyttan losunarhraða 40 mg
stada arzneimittel ag - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 40 mg
Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
methylphenidate stada hart hylki með breyttan losunarhraða 60 mg
stada arzneimittel ag - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 60 mg
Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
tamsulosin viatris (tamsulosin mylan 0,4 mg hart hylki með breyttan losunarhraða) hart hylki með breyttan losunarhraða 0,4 mg
viatris limited - tamsulosinum hýdróklóríð - hart hylki með breyttan losunarhraða - 0,4 mg
Europeiska unionen -
isländska -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
zesuva (sunitinib alvogen) hart hylki 12,5 mg
zentiva k.s.* - sunitinibum inn - hart hylki - 12,5 mg
Island -
isländska -
LYFJASTOFNUN (Icelandic Medicines Agency)
zesuva (sunitinib alvogen) hart hylki 25 mg
zentiva k.s.* - sunitinibum inn - hart hylki - 25 mg